Corrections:

Ido D. Weiss¹, Lyn M. Huff², Moses O. Evbuomwan³, Xin Xu¹, Hong Duc Dang¹, Daniel S. Velez¹, Satya P. Singh¹, Hongwei H. Zhang¹, Paul J. Gardina⁴, Jae-Ho Lee⁵, Liza Lindenberg⁶, Timothy G. Myers⁴, Chang H. Paik⁵, David S. Schrump⁷, Stefania Pittaluga³, Peter L. Choyke⁶, Tito Fojo² and Joshua M. Farber¹

¹ Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
² Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
³ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
⁴ Genomic Technologies Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
⁵ Radiopharmaceutical Laboratory, Nuclear Medicine Division, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA
⁶ Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
⁷ Thoracic Epigenetics Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Published: October 02, 2018

This article has been corrected:

On page 73395, the following sentences have been updated to read, "Dosimetry for 64Cu- plerixafor calculated from this single patient gave an Effective Dose of 0.283 rem/mCi, and a total of 2.43 rem from the dose of 8.6 mCi. The organs that contributed the most to the Effective Dose were the liver and bone marrow (0.0606 and 0.0760 rem/mCi, respectively)".

Similar to results in mice, the liver had the highest uptake of the tracer, with unbound tracer excreted through the kidneys [31, 32]. Significant uptake was also seen in organs of the immune system, including spleen, vertebral bodies (bone marrow), and lymph nodes (Figure 4 and Supplementary Figure 6). Of additional interest, uptake of 64Cu-plerixafor was absent from a number of vertebral bodies in the thoracolumbar spine that were within the region of prior radiation therapy (Figure 4 and Supplementary Figure 6). Dosimetry for 64Cu-plerixafor calculated from this single patient gave an Effective Dose of 0.283 rem/mCi, and a total of 2.43 rem from the dose of 8.6 mCi. The organs that contributed the most to the Effective Dose were the liver and bone marrow (0.0606 and 0.0760 rem/mCi, respectively). PET/CT sections (Figure 4B) showed variable uptake in the multiple pulmonary nodules.

Original article: Oncotarget. 2017; 8:73387-73406. DOI: https://doi.org/10.18632/oncotarget.19945.